Waitan Ludi Policy Terminal

Country-interest evidence · pilot

Trade inferences use UN Comtrade, with China as reporter. Country connections indicate potential trade relevance, not measured harm, firm-level exposure or legal applicability. Inward measures concern exporters to China; competition with Chinese exports in third markets is not assessed.

Inspect implementing jurisdictions and partner evidence · 46 relationships

Argentina: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 42,419,077

Australia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 215,472,215

Austria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 399,904,647

Belgium: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 1,250,824,208

Bulgaria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 4,490,712

Brazil: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 31,805,587

Canada: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 548,115,825

Switzerland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 2,897,331,803

Cyprus: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 2,926,265

Czech Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 1,415,915

Germany: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 7,403,150,465

Denmark: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 965,478,913

Spain: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 658,310,865

Finland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 119,997,547

France: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 3,202,265,000

United Kingdom: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 884,758,236

Greece: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 242,780,544

Hong Kong, China: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 626,768,104

Hungary: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 67,058,023

Indonesia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 3,582,885

India: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 129,977,615

Ireland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 7,760,048,930

Israel: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 46,327,013

Italy: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 2,704,155,104

Japan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 1,565,811,607

Korea, Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 84,311,295

Lithuania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 3,838,332

Mexico: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 3,570,743

Malta: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 1,522,448

Netherlands: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 709,320,940

Norway: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 24,262,663

New Zealand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 66,749,431

Poland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 32,436,723

Portugal: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 1,479,966

Romania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 4,789,899

Russian Federation: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 2,318,060

Singapore: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 134,359,683

Slovenia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 11,025,261

Sweden: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 1,841,507,374

Thailand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 10,827,534

Chinese Taipei: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 214,833,803

Uruguay: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 25,034,998

United States: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 6,306,541,184

Vietnam: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 11,204,347

South Africa: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62599 · recorded trade USD 20,950,479

Implementing jurisdiction: China · intervention 62599

Assessment states

Trade-based partners recorded

Measures

Capital grant

Prefectural · origin: Chinese firms or production in China · locality: Local firms · CPC 352 · in force from 2024-11-01 · until 2026-12-31 · Keyword screen (unreviewed)

Implemented by China (subnational) · affects 45 partners (inferred from trade data, 2023 trade): Ireland, Germany, United States, France, Switzerland, Italy …

Stated rationale

Industrial upgrading & strategic competitiveness · document title or opening · unreviewed 为深入贯彻落实党中央、国务院和省委、省政府关于推进新型工业化、发展新质生产力的决策总署

对1类化学药、1类生物制品、中药创新药，按研发不同阶段给予后补助。

Supports production in a place, so favours that place by rule.

Asymmetric provisions

Ownership, own-brand or own-IP test (自主品牌, 自主知识产权, 股比)

Disadvantages: foreign-owned firms · Keyword screen (unreviewed)

获批拥有自主知识产权的二类、三类医疗器械注册产品（生化类诊断试剂、低值耗材除外），按单品种不超过实际投入研发费用的20%给予补助，最高分别不超过200万元、500万元。

Ownership, own-brand or own-IP test (自主品牌, 自主知识产权, 股比)

Disadvantages: foreign-owned firms · Keyword screen (unreviewed)

2023年以来在国家级创新创业大赛中获奖、且具有核心自主知识产权的生物医药领域企业，以“奖补＋基金”方式给予支持，其中：奖补按照总投资（含设备、技术及软件等投入）规模、给予最高1000万元的分档支持；

Same central policy, other provinces

关于印发“十四五”医药工业发展规划的通知 · 工信部联规〔2021〕217号 · 2021-12-22 · answered in 1 province held · trace it ↗

Province	First document citing it	Dated	Lag
Zhejiang	this document	2024-10-11	1024 d

Held documents only: these are counts of what we have collected, not of what each province issued.

Full text

甬经信消〔2024〕124号各区（县、市）人民政府办公室，各有关单位：为贯彻落实《宁波市人民政府办公厅关于加快发展新质生产力全力推进新型工业化的若干意见》（甬政办发〔2024〕26号），加快推进我市生物医药产业绿色化、智能化、高端化发展，现将《宁波市加快推进生物医药产业发展若干意见》印发你们，请结合实际认真做好贯彻落实。宁波市经济和信息化局宁波市财政局宁波市制造业高质量发展（数字经济发展）领导小组办公室宁波市科学技术局宁波市市场监督管理局 2024年9月27日宁波市加快推进生物医药产业发展若干意见为深入贯彻落实党中央、国务院和省委、省政府关于推进新型工业化、发展新质生产力的决策总署，根据《“十四五”医药工业发展规划》、《浙江省医药产业发展“十四五”规划》、《宁波市加快打造“361”万千亿产业集群行动方案（2023-2027年）》等相关文件精神，为加快推进我市生物医药产业绿色化、智能化、高端化发展，特提出以下政策意见。一、支持对象和范围（一）支持对象。在宁波市从事生物医药研发、生产和服务的企事业单位（财政全额拨款的除外）。（二）支持范围。包括化学药、生物制品、中药及天然药物、兽药等制药及原辅料领域；数字诊疗设备、医用治疗、监护和康复设备、临床检验设备及核心部件，体外诊断产品、植介入器械、高值医用耗材、人工智能辅助诊断技术及产品等。二、支持产业研发创新（一）支持新药研发。对1类化学药、1类生物制品、中药创新药，按研发不同阶段给予后补助。完成临床前研究并取得临床试验批件，给予一次性300万元补助；完成Ⅱ期临床试验并进入Ⅲ期临床试验的（包含中药人用经验临床研发阶段），按不超过Ⅰ、Ⅱ期临床试验实际投入研发费用的30%给予补助，最高不超过1000万元；完成Ⅲ期临床试验提交注册审批并受理的，按不超过Ⅲ期临床试验实际投入研发费用的30%给予补助，最高不超过3000万元。完成Ⅱ期临床试验允许紧急上市提交注册审批并受理的1类创新药，按不超过Ⅰ、Ⅱ临床试验实际投入研发费用的30%给予补助，最高不超过3000万元。取得药品注册证的，再给予1000万元奖励。单个企业每年最高不超过1亿元。对2类化学药、2类生物制品、中药改良型新药，按研发不同阶段给予后补助。完成临床前研究并取得临床试验批件，给予一次性100万元补助；完成Ⅱ期临床试验并进入Ⅲ期临床试验的（包含中药人用经验临床研发阶段），按不超过Ⅰ、Ⅱ期临床试验实际投入研发费用的20%给予补助，最高不超过500万元；完成Ⅲ期临床试验提交注册审批并受理的，按不超过Ⅲ期临床试验实际投入研发费用的20%给予补助，最高不超过1000万元；取得药品注册证的，再给予500万元奖励。单个企业每年最高不超过2000万元。取得药品批准文号的3类化学药及生物制品仿制药，按不超过实际投入研发费用的20%给予补助，最高不超过500万元。取得4类化学药、古代经典名方中药复方制剂及同名同方中药、1-3类兽药注册证，按不超过实际投入研发费用的20%给予补助，最高不超过300万元。单个企业每年最高不超过1000万元。（责任单位：市科技局、市经信局、市市场监管局）（二）支持医疗器械创新。获批拥有自主知识产权的二类、三类医疗器械注册产品（生化类诊断试剂、低值耗材除外），按单品种不超过实际投入研发费用的20%给予补助，最高分别不超过200万元、500万元。获得创新二类、三类医疗器械注册证的，单品种分别再给予一次性100万元、300万元奖励。单个企业每年最高不超过2000万元。（责任单位：市科技局、市经信局、市市场监管局）（三）提升仿制药品水平。对仿制药获得药品批准文号后，申请国家一致性评价并获通过的药品（不同规格视为一个品种），每个品种按不超过一致性评价过程中实际投入研发费用的20%给予补助。（责任单位：市经信局、市市场监管局）三、支持药械成果转化（一）鼓励药械就地转化。对生产企业引入注册批件并实现产业化的创新药（含获批紧急使用的药品）、改良型新药、化学仿制药、生物制剂类药、古代经典名方中药复方制剂等，每个产品按不超过注册证购买费用的20%予以一次性补助。（责任单位：市经信局、市市场监管局）（二）支持生物制造成果转化。对获得应用在生物医药领域的生物制造（或合成生物）类由国家知识产权局授权的发明专利，且实现产业化的企业，每项专利给予50万元的一次性补助。（责任单位：市经信局、市市场监管局）（三）鼓励受托生产。支持企业承接市外药品上市许可持有人和医疗器械注册人委托的药械产品生产，对新获得生产许可并实现产业化的药械产品（不同规格视为一个品种），每个产品给予10万元的一次性奖励。（责任单位：市经信局、市市场监管局）（四）加强临床研究成果转化激励。支持医疗机构开展临床研究及成果转化。对在临床研究成果转化中做出主要贡献的公立医院人员，允许其职务科技成果转化现金奖励一次性增加公立医院薪酬总量，不计入薪酬水平和总量核定基数。健全职务科技成果转化收益分配机制、将不低于奖励总额的70%奖励给成果完成人（团队），将不低于奖励总额的5%奖励给技术转移机构人员和管理人员。（责任单位：市卫生健康委、市人力社保局）四、支持企业培育和项目招引（一）支持高成长潜力企业招引。2023年以来在国家级创新创业大赛中获奖、且具有核心自主知识产权的生物医药领域企业，以“奖补＋基金”方式给予支持，其中：奖补按照总投资（含设备、技术及软件等投入）规模、给予最高1000万元的分档支持；对符合基金投资条件的项目同步给予产业基金资金支持。（责任单位：市经信局、市科技局、市发改委、市市场监管局、市委金融办、市投资促进局）（二）支持新建产业投资项目。对零地技改和新建生物医药项目，投资规模2000万元（含）以上，按照不超过实际投入总额（含设备、技术、专利、软件及洁净车间相关安装建设费用）的15%给予补助，最高不超过2000万元。（责任单位：市经信局、市发改委、市科技局、市自然资源和规划局、市生态环境局、市卫生健康委、市市场监管局、市委金融办、市投资促进局）（三）支持中医药产业品牌创建和生产体系提升。对入选“浙产中药”、“中国医药·品牌榜”的中药产品，分别给予20万元、50万元的补助。鼓励中医药企业开展工艺创新，提升生产体系水平，对已在国内上市的中药产品，获得美国（FDA）、欧盟（CE）临床试验（IND）批件，每个产品给予100万元的补助。（责任单位：市经信局、市市场监管局）五、支持产业集聚发展（一）支持建设公共服务平台。经评审认定，对总投资1000万元以上的药物研发、检验检测等公共服务平台，按照实际投入（含设备、技术及软件等投入）规模、服务绩效等，给予最高1000万元的分档补助。（责任单位：市经信局、市科技局、市市场监管局）（二）提升产业空间承载能力。在符合国土空间规划的前提下，合理保障生物医药产业项目用地指标。统筹安排三类工业用地建设若干个可承载原料药、中间体等产品的绿色制造园区。在确保产业园区环境质量和安全的前提下，依法统筹保障产业园区内合规项目污染物排放总量和能耗指标。（责任单位：市自然资源和规划局、市生态环境局、市经信局）（三）支持园区项目引培和规模提升。对符合要求的生物医药产业园区，按照引培企业数量、产业规模及增速、园区运营情况等指标，给予最高200万的分档奖励。对园区内符合基金投资条件的项目，政府产业基金给予相应支持。（责任单位：市经信局、市市场监管局）六、支持市场拓展（一）鼓励创新产品推广应用。鼓励优质创新产品、获得国际市场认证的高质量产品推广应用。支持药品和医用耗材创新产品挂网，优化创新高端医疗器械进入医院的招投标流程，深入推进医疗机构配置使用大型医用设备工作。积极引导通过仿制药一致性评价的药品企业参加各级集中带量采购，鼓励医疗机构使用集采中选产品。（责任单位：市医保局、市卫生健康委、市经信局、市市场监管局）（二）支持国际资质认证。对首次通过美国食品药品监督局（FDA）、欧洲药品管理局（EMA）、欧洲统一（CE）、日本药品医疗器械局（PMDA）、世界卫生组织（WHO）等国际权威认证的药械企业，按审计后实际发生费用（含技术改造、注册认证费、海外临床试验费）的30%给予一次性补助。（责任单位：市市场监管局；配合单位：市经信局） (三)支持开发推广适老化产品。对首次入选国家《老年用品产品推广目录》的医疗器械领域产品，每个产品给予20万元补助。（责任单位：市经信局、市民政局、市市场监管局）七、加强产业金融支持（一）拓宽生物医药企业融资渠道。引导金融机构加强生物医药企业全生命周期金融服务，推动银行机构积极满足企业合理有效融资需求，鼓励保险机构开发专项保险产品，支持优质生物医药企业上市融资；推动各级各类国资基金、政府投资基金组建生物医药产业子基金，以市场化运作机制，撬动社会资本，加大对生物医药产业优质项目支持。（责任单位：市委金融办、市经信局、市投资促进局、市国资委、市财政局、市金投控股集团、市通商集团）（二）降低企业经营风险。积极鼓励相关保险机构提供生物医药人体临床试验责任保险、生物医药产品责任保险等定制化综合保险产品，对符合条件的生物医药机构和企业，按其实际缴纳保费的50%予以资助，单个保单最高不超过100万元，单个企业每年资助最高不超过200万元。（责任单位：市经信局、市委金融办、市卫生健康委）鼓励企业加大数字化、绿色化、研发投入，对数字化等级二级（含）以上且完成绿色化改造的制造业企业，享受本若干意见内100%的市级财政奖补政策;未达到数字化等级二级或未完成绿色化改造的制造业企业，减半享受本若干意见内的市级财政奖补政策。对年度无研发经费内部支出的制造业企业，不予享受本若干意见内的市级财政奖补政策。成立三年内（含）的初创型企业和高端人才及团队实施的科技计划项目及创业创新项目等暂不具备实施数字化、绿色化改造条件的企业除外。本政策自2024年11月1日起施行，至2026年12月31日止。

Ask the evidence.

关于印发《宁波市加快推进生物医药产业发展若干意见》的通知

Country-interest evidence · pilot

Measures

Asymmetric provisions

Same central policy, other provinces

Full text